JP2022500076A5 - - Google Patents

Info

Publication number
JP2022500076A5
JP2022500076A5 JP2021537505A JP2021537505A JP2022500076A5 JP 2022500076 A5 JP2022500076 A5 JP 2022500076A5 JP 2021537505 A JP2021537505 A JP 2021537505A JP 2021537505 A JP2021537505 A JP 2021537505A JP 2022500076 A5 JP2022500076 A5 JP 2022500076A5
Authority
JP
Japan
Prior art keywords
sequence
seq
fusion protein
mutations
antibody
Prior art date
Application number
JP2021537505A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022500076A (ja
JP7623006B2 (ja
JPWO2020053239A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/074153 external-priority patent/WO2020053239A1/en
Publication of JP2022500076A publication Critical patent/JP2022500076A/ja
Publication of JPWO2020053239A5 publication Critical patent/JPWO2020053239A5/ja
Publication of JP2022500076A5 publication Critical patent/JP2022500076A5/ja
Application granted granted Critical
Publication of JP7623006B2 publication Critical patent/JP7623006B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021537505A 2018-09-11 2019-09-11 特異的結合剤により認識されるエピトープタグ Active JP7623006B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18193663 2018-09-11
EP18193663.4 2018-09-11
EP19160485.9 2019-03-04
EP19160485 2019-03-04
PCT/EP2019/074153 WO2020053239A1 (en) 2018-09-11 2019-09-11 Epitope tags recognized by specific binders

Publications (4)

Publication Number Publication Date
JP2022500076A JP2022500076A (ja) 2022-01-04
JPWO2020053239A5 JPWO2020053239A5 (https=) 2022-09-16
JP2022500076A5 true JP2022500076A5 (https=) 2022-09-16
JP7623006B2 JP7623006B2 (ja) 2025-01-28

Family

ID=68138006

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021537505A Active JP7623006B2 (ja) 2018-09-11 2019-09-11 特異的結合剤により認識されるエピトープタグ

Country Status (5)

Country Link
US (3) US12365705B2 (https=)
EP (1) EP3849996B1 (https=)
JP (1) JP7623006B2 (https=)
CN (1) CN113195516B (https=)
WO (1) WO2020053239A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023216437A1 (en) * 2022-02-02 2024-08-15 BioNTech SE Agents and methods for targeted delivery of nucleic acids to cells
AU2023214781A1 (en) * 2022-02-02 2024-08-15 BioNTech SE Cyclic epitope tags
EP4472672A1 (en) * 2022-02-02 2024-12-11 BioNTech SE Agents and methods for targeted delivery to cells
CA3251998A1 (en) 2022-05-16 2023-11-23 Byondis B.V. Novel masked antibodies
CN117802045A (zh) 2022-09-30 2024-04-02 北京恩康医药有限公司 一种工程化细胞外囊泡的构建及其应用
US12565665B2 (en) 2022-12-21 2026-03-03 Trustees Of Boston University Compositions and methods for controlled mRNA translation and stability
WO2024172152A1 (ja) * 2023-02-17 2024-08-22 国立大学法人 東京大学 細胞外小胞の運命記録システム
WO2025021277A1 (en) * 2023-07-21 2025-01-30 BioNTech SE Agents and methods for targeted delivery of cytokines to immune cells
EP4520768A1 (en) 2023-09-06 2025-03-12 BioNTech SE Vhh-ch3 fusion proteins
WO2025078418A1 (en) 2023-10-10 2025-04-17 Nano Tag Biotechnologies Gmbh Humanized single-domain antibodies binding to epitope tags
AR134082A1 (es) 2023-10-11 2025-12-03 BioNTech SE Agentes y métodos para la administración dirigida de células efectoras inmunitarias
WO2025219955A1 (en) * 2024-04-17 2025-10-23 BioNTech SE Soluble tcrs and methods of use thereof
CN120923600A (zh) * 2024-05-09 2025-11-11 福建医科大学 一种超稳定红色荧光蛋白
US20260015401A1 (en) * 2024-07-10 2026-01-15 Angeles Therapeutics, Inc. Compositions and methods comprising epitopes and polypeptides
WO2026019685A1 (en) * 2024-07-17 2026-01-22 Harpoon Therapeutics, Inc. Her2 targeting trispecific protein for treatment of cancer
CN118909142A (zh) * 2024-08-07 2024-11-08 北京爱思益普生物科技股份有限公司 Irak4蛋白的制备方法及其所采用的融合蛋白

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU701578B2 (en) * 1992-08-21 1999-02-04 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US20040014955A1 (en) 2001-12-17 2004-01-22 Carlos Zamudio Identification of essential genes of cryptococcus neoformans and methods of use
WO2004041867A2 (en) * 2002-11-08 2004-05-21 Ablynx N.V. Camelidae antibodies against imminoglobulin e and use thereof for the treatment of allergic disorders
US20090022720A1 (en) * 2007-07-20 2009-01-22 Stephan Fischer Conjugate of an antibody against CD4 and antifusogenic peptides
US7678883B2 (en) * 2007-07-25 2010-03-16 E.I. Du Pont De Nemours And Company Solubility tags for the expression and purification of bioactive peptides
GB201008682D0 (en) 2010-05-25 2010-07-07 Vib Vzw Epitope tag for affinity based applications
CN107406514B (zh) * 2014-11-03 2021-11-30 默克专利有限公司 可溶内含肽融合蛋白以及用于纯化生物分子的方法
EP3168306A1 (en) 2015-11-16 2017-05-17 ChromoTek GmbH Epitope tag and method for detection and/or purification of tagged polypeptides

Similar Documents

Publication Publication Date Title
JP2022500076A5 (https=)
JP7623006B2 (ja) 特異的結合剤により認識されるエピトープタグ
JPWO2020053239A5 (https=)
Kipriyanov et al. Affinity enhancement of a recombinant antibody: formation of complexes with multiple valency by a single-chain Fv fragment–core streptavidin fusion
Dübel et al. Bifunctional and multimeric complexes of streptavidin fused to single chain antibodies (scFv)
JP2020186248A5 (https=)
JP2017518748A5 (https=)
JP2019521643A5 (https=)
US11384141B2 (en) Serum albumin binding antibodies for tuneable half-life extension of biologics
RU2016149596A (ru) Новые полипептиды со специфическим связыванием и пути их применения
JP2018532372A5 (https=)
WO2021092075A1 (en) IL-2RβγC BINDING COMPOUNDS
JP2014502149A5 (https=)
JP7702111B2 (ja) ナノボディー交換クロマトグラフィー
CN107849147A (zh) 基于二泛素突变蛋白的Her2 结合蛋白
CN105968201A (zh) 针对前列腺特异性膜抗原的单域重链抗体
JP5042237B2 (ja) 血小板抗原特異抗体の結合を中和するペプチドアプタマー並びにそれを含む診断及び治療への応用
WO2021207613A1 (en) Frb antibodies
JP2019523782A5 (https=)
Käkönen et al. Purification and characterization of recombinant osteocalcin fusion protein expressed inEscherichia coli
US7741053B2 (en) Processes for purification of recombinant proteins
CN104311654A (zh) 一种cide3多肽及其抗体的制备和应用
Chen In vitro production of multimeric and multispecific nanobodies with the peptidisc technology
CN107629112B (zh) 一种高亲和性lc3蛋白靶向肽及其应用
Aguilar et al. MAP dendrimer elicits antibodies for detecting rat and mouse GH‐binding proteins